Case Analysis of Drug-induced Microscopic Colitis due to Long-term Use of Proton Pump Inhibitor

doi:10.19803/j.1672-8629.2021.02.20

Abstract

Abstract: Objective To analyze the process of diagnosing and treating a rare case of microscopic colitis detected during histopathological examination of a patient with chronic diarrhea, who had long been taking a proton pump inhibitor (PPI). Methods Related literature was reviewed while the characteristics of drug-induced microscopic colitis and the mechanism of PPI-induced microscopic colitis were analyzed to determine the adverse drug reactions in this case. Results Irregular and long-term use of a PPI was likely to lead to drug-induced microscopic colitis. Conclusion Clinical pharmacists ought to use their knowledge of pharmacy to quickly discover the adverse reactions caused by drugs in clinical diagnosis and treatment, which can provide reference for the rational use of PPIs in clinical practice.

Key words: drug-induced microscopic colitis, proton pump inhibitor, adverse drug reactions

CLC Number:

R969.3

KONG Bin, LIN Rongfang, LIU Xiaoxia. Case Analysis of Drug-induced Microscopic Colitis due to Long-term Use of Proton Pump Inhibitor[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 194-195.

References

[1] Gao MS, Chen YJ.Risk analysis of the application of proton pump inhibitors[J]. Chinese General Practice(中国全科医学), 2015, 18(20): 2448-2450.
[2] Li MH, Feng Q,Li XY, et al.Research progress of clinical applications and adverse reactions of lansoprazole[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(12): 729-731.
[3] Li M, Su X,Shan YY.Analysis of application reasonability of proton pump inhibitors in hospital intensive care units[J].Northwest Pharmaceutical Journal(西北药学杂志), 2018,33(6): 837-840.
[4] Verhaegh F,Masclee AA.High risk of drug-induced microscopic colitis with concomitant use of NSAIDS and proton pump inhibitors[J].Annals of Pharmacotherapy,2016,43(9):1004-1013.
[5] Ernest HL, Melissa B, Hunglaw YT, et al.Association between proton pump inhibitors and microscopic colitis:implications for practice and future research[J].Alimentary Pharmacology Therapeutics, 2017, 51(3):253-263.
[6] Lu YX, Li ZJ.Microscopic colitis: a cause of diarrhea easy to miss[J].New Medicine(新医学), 2014, 45(4): 226-230.
[7] Xu XM, Huang GM.Advances in study on treatment of microscopic colitis[J]. Chinese Journal of Gastroenterology(胃肠病学) , 2015, 20(1): 45-48.
[8] Zhao XT, Wang MC.Relationship between proton pump inhibitor and clostridium difficile infection[J]. Medical Recapitulate(医学综述), 2018, 24(8): 1530-1534.
[9] Xie TT, Guo DH, Zhao SY, et al.Analysis of 1298 cases of adverse drug reactions induced by proton pump inhibitors in military hospitals[J].Pharmac-eutical Care and Research(药学服务与研究), 2018, 18(3): 173-176.
[10] Zhang YJ, Guo SG, Fang J, et al.Rational usage of proton pump inhibitors in inpatients in a hospital[J]. China Pharmaceuticals(中国药业), 2017, 26(21): 82-84.
[11] Liang YH, Hou YM, Huang L.Analysis of proton pump inhibitors application in a tumor hospital from 2013 to 2015[J]. Northwest Pharmaceutical Journal(西北药学杂志), 2017, 32(3): 385-387.
[12] Li HY, Hu B.Pharmaceutical care practice of proton pump inhibitors and its interactions with other drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒) , 2016, 13(7): 429-432.

[1]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[2]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[3]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[4]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[5]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	LI Xingren, SHEN Aizong, SU Dan. Evaluation of the rationality of proton pump inhibitors in preventing perioperative stress related mucosal disease in biliary and pancreatic surgery [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1022-1026.
[8]	ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
[9]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[10]	WANG Shuwei, YIN Jinjun, WANG Bing, SONG Caiping, YANG Fujun. Axitinib tablets combined with toripalimab injection in the treatment of renal cancer-induced central retinal artery occlusion: a case report [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 825-828.
[11]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[12]	LI Tan, ZHANG Yang, ZHANG Wangde, WANG Yun. Efficacy and safety of different analgesia drugs in the treatment of lower extremity ischemic pain [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 680-683.
[13]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[14]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[15]	CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin. Analysis of reports of allergic shock in Chongqing between 2015 and 2020 [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.